Profile: Progenics Pharmaceuticals Inc (PGNX.OQ)
10 Dec 2013
Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company. The Company focuses on the research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. The Company is also engaged in research to identify multiplex phosphoinositide 3-kinase (PI3K) inhibitors for blocking signaling pathways in the growth of aggressive cancers. Progenics also continues its research and development efforts for drug candidates focused on oncology. In gastroenterology, its first commercial product is RELISTOR (methylnaltrexone bromide) subcutaneous injection. Its principal product candidate is PSMA ADC, a fully human monoclonal antibody-drug conjugate (ADC) directed against prostate specific membrane antigen (PSMA), a protein found at high levels on the surface of prostate cancer cells and also on the neovasculature of a number of other types of solid tumors. All of the Company’s operations are conducted at its facilities in Tarrytown, New York. In October 2012, CytoDyn Inc acquired Pro 140, an experimental humanized monoclonal antibody (mAb) targeting the CCR5 receptor for the treatment and prevention of HIV, from Progenics. In January 2013, the Company acquired Molecular Insight Pharmaceuticals, Inc.
Opioid-based medications such as morphine and codeine are used to control moderate-to-severe pain in patients receiving palliative care, undergoing surgery, experiencing chronic pain or with other medical conditions. Opioids relieve pain by interacting with receptors located in the brain and spinal cord, but also activate receptors in the gut, often resulting in constipation, referred to as opioid-induced constipation (OIC). As a result of OIC, many patients may stop or reduce their opioid therapy, opting to endure pain in order to obtain relief from their OIC and its associated side effects.
RELISTOR, the first approved treatment for OIC that addresses the underlying mechanism of this condition, is a selective, peripherally acting, mu-opioid-receptor antagonist that decreases the constipating side effects induced by opioid pain medications in the gastrointestinal tract without diminishing the ability of these medications to relieve pain. The Company is also developing subcutaneous RELISTOR for treatment of OIC outside the advanced-illness setting, in individuals with non-cancer pain. The Company has presented preclinical data on monoclonal antibodies against toxins produced by C. difficile showing these monoclonal antibodies to have neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model.
Through PSMA Development Company, its wholly owned subsidiary, the Company conducts research and development programs directed at prostate specific membrane antigen (PSMA), a protein that is abundantly expressed on the surface of prostate cancer cells as well as cells in the newly formed blood vessels of many other solid tumors.
The principal focus of these efforts is its fully human monoclonal ADC, which is designed to deliver a chemotherapeutic agent to cancer cells by targeting the three-dimensional structure of the PSMA protein on these cells and binding to and internalizing within the cell. It believes a PSMA-directed therapy may have application in prostate cancer and solid tumors of other types of cancer.
The Company competes with Adolor Corporation, Sucampo Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Nektar Therapeutics-AstraZeneca PLC, Alkermes, Inc., Theravance, Inc., Mundipharma International Limited and Movetis NV.
Progenics Pharmaceuticals Inc
777 Old Saw Mill River Road
TARRYTOWN NY 10591